Added to YB: 2026-04-15
Pitch date: 2026-04-08
RPRX [neutral]
Royalty Pharma plc
+18.72%
current return
Author Info
No bio for this author
Company Info
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States.
Market Cap
$24.3B
Pitch Price
$47.55
Price Target
N/A
Dividend
1.71%
EV/EBITDA
N/A
P/E
28.82
EV/Sales
14.64
Sector
Pharmaceuticals
Category
value
Patient Opportunity Equity Strategy Portfolio Holding: Royalty Pharma plc
RPRX (holding update): World's largest biopharma royalty buyer, gained 25.6% in Q1. Provides capital to drug developers for future revenue share, generating predictable cash flows. Maintains strong deal discipline w/ low-teens unlevered IRR, high-teens levered returns. Undervalued vs cash flow quality. Expects mid-teens shareholder returns via royalty growth, dividend growth & buybacks.
Read full article (1 min)